Acs Research - Theorylab

Cancer drugs that target “the machinery required for cell division” have been used successfully in clinics for decades. But these drugs have limitations. Many patients develop resistance and the side effects can be severe, because these drugs—in addition to targeting rapidly dividing tumor cells—also kill healthy cells. Dr. Holland’s lab is searching for vulnerabilities in cell division that are unique to cancer cells. And he is building on some of his findings to develop a novel anti-cancer strategy that allows for the specific killing of proliferating tumor cells without affecting healthy dividing cells. Andrew Holland, PhD, is Associate Professor in the Department of Molecular Biology and Genetics and the Department of Oncology at Johns Hopkins Hospital. He’s also a two-time American Cancer Society grantee. He recently received a Mission Boost Grant, which are designed to support select current and past ACS grantees specifically for the translation of their research to human testing. 2:23 – On what it